https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society orsodn author: Corresponding Abbreviations: or CO glucose to as them such oxidise molecules and fuel acids, up fatty take cells Animal Society g Nutrition the of Proceedings as eur ytm omntrtesaeo h battery, the of state utilise the that monitor to machines ADP, electric systems to as or require computers back Just laptop cars) ATP as battery. (such of batteries conversion the rechargeable the draining by (e.g. energy thus driven require activities are movement) cellular and and other secretion converting most division, by whereas growth, battery ATP, this the Extending to up likened battery. ADP be charges rechargeable can catabolism a which in analogy, ATP, pro- to chemicals this ADP the during convert to released to used energy is the cess of Much catabolism. h uhr21 is ulse nie1 oebr2010 November 11 online published First 2010 Author The h umrMeigo h urto oit otdb h ctihScinwshl tHro-atUiest,Eibrhon Edinburgh University, Heriot-Watt at held was Section Scottish the by hosted Society Nutrition the of Meeting Summer The nrysnigb h M-ciae rti iaeadiseffects its and kinase protein AMP-activated the by sensing Energy https://www.cambridge.org/core C,aey-o abxls;AP,APatvtdpoenkns;mO,mmaintarget-of-rapamycin. mammalian mTOR, kinase; protein AMP-activated AMPK, carboxylase; acetyl-CoA ACC, hngyoe eoe eltdatreecs,bti wthdofaana ona glycogen as soon as again activated off rapidly switched is is synthesis glycogen. but glycogen replenished. in glycogen exercise, that are ends after ensures phosphorylating stores non-reducing this depleted by that exposed becomes surface hypothesis synthesis by glycogen the when the inhibited glycogen on is to inhibit working AMPK bind are can that target-of- biogenesis. to We shown it mitochondrial sub-fraction have mammalian and a We and particle, causes synthase. the expression glycogen that GLUT4 of the domain increased adaptations glycogen-binding of inactivation chronic a as the contains via such of AMPK glycogen some the exercise, later causes off of endurance also switching (the activation translocation to while AMPK promoting synthesis oxidation, Prolonged (by acid pathway). protein rapamycin fatty uptake in and glucose and essential membrane) activates not synthesis the acutely processes to it energy-requiring GLUT4 Thus, catabolic off transporter on term. switching the switches while short in AMPK occur ATP, the activated, that generate Once changes exercise. that metabolic energy sustained endurance the processes cellular by to in in triggered bind resistance important therefore fall reversibly particularly from is a be transition activation that (signalling to AMPK ratio sites appears muscle, and In contains AMP:ATP contraction, kinase. cellular AMPK the in muscle. on increase expressed, switching skeletal an ubiquitously status) with in Although ATP, levels. understood or body regulator best whole AMP a and and is status, cellular function energy the cellular both its of at sensor balance a energy is of (AMPK) kinase protein AMP-activated The . ofrneo Ntiinadhat:cl ocommunity’ to cell health: and ‘Nutrition on Conference https://doi.org/10.1017/S0029665110003915 rfso ..Hri,fax Hardie, D.G. Professor olg fLf cecs nvriyo ude udeD15H UK 5EH, DD1 Dundee Dundee, of University Sciences, Life of College . IPaddress: (2011), 170.106.35.234 uce xrie ye2daee:Nutraceuticals diabetes: 2 Type Exercise: Muscle: 2 i h rcs of process the via 70 + nmsl metabolism muscle on 29 doi:10.1017/S0029665110003915 92–99 , 418 857 mi [email protected] email 385507, 1382 44 , on lnr Lecture Plenary 29 Sep2021 at02:51:01 .GaaeHardie Grahame D. 8Jn– uy2010 July June–1 28 pcfi mn cd,uulysrn r esfrequently, less by or, proteins serine of usually target chains acids, side of to amino ATP function specific from the groups phosphate modify transferring that type-2 system. and zymes the obesity in interested as understand particularly such to been balance, have wish this diabetes, energy who achieving (AMPK), of for Researchers kinase disorders responsible eukaryotes. this system protein in of carbon major topic task AMP-activated the of The is utilisation. the consumption which ATP and is of uptake rate review the and of to ratio rates nutrients ATP:ADP their the monitor match to systems require cells , subjectto theCambridgeCore termsofuse,available at rti iae,icuigAP,aesgaln en- signalling are AMPK, including kinases, Protein https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society iaekinase- kinase aaye yteCa the by catalysed o euts,wr identical were 3-hydroxy-3-methylglutaryl- reductase, acetyl- and CoA i.e. regulatory (ACC) synthesis, key cholesterol carboxylase and CoA the acid inactivate fatty of previously and enzymes kinases phosphorylate protein to that found recognised he when other author in conditions and hormones about like messages molecules locations. carry to that changes and to cytokines conditions, response in local modulated mechanism is in function important cell most which the by is phosphorylation protein iaectltcsbnt,acutn o ery2 fall of 2% protein nearly 500 for over accounting genes the encoded subunits, of it catalytic sequencing that kinase revealed when of genome emphasised importance to human was targeting The kinases their the as- compartments. protein affects their change or subcellular phosphory- changes proteins, or particular cases, degradation, other off, with for other sociation proteins or In targets regulators. on lation other activity it to enzyme metabolic enzyme response a is target switch the target of the can function if the example, phosphatases, in For protein change protein. by marked a catalysed triggers reversed reaction often is different which a modification, by This tyrosine. or threonine Ca the be intracellular of also in can displacement rise system causes a The ADP by AMP. in towards activated rise reaction kinase meta- prevents a during adenylate also because rises and stress AMP, effect, signal, bolic allosteric activating an The via the increases dephosphorylation. 10-fold phosphatases. that further change protein back a conformational converted by a activity rapidly causes form is AMP of inactive it Binding AMP dephosphorylated, of 100- the absence activity to the the their increasing in form, indicate However, phosphorylated fold. AMPK its con- to of continually AMPK (LKB1) forms kinase verts upstream three The activity. the kinase relative below Numbers system. 1. Fig. h uloie5 nucleotide the h MKwsfis endi h ae18sb the by 1980s late the in defined first was AMPK The (1) https://www.cambridge.org/core euaino h M-ciae rti iae(AMPK) kinase protein AMP-activated the of Regulation hsgetdvriyrflcstelklho that likelihood the reflects diversity great This . b (CaMKK 0 AP hc assisactivation its causes which -AMP, 2 . + b https://doi.org/10.1017/S0029665110003915 atvtdkns calmodulin-dependent kinase -activated ). . IPaddress: (2) enmdi MKafter AMPK it named We . 2 + u ophosphorylation to due , 170.106.35.234 MKadmsl eaoim93 metabolism muscle and AMPK , on (3) 29 Sep2021 at02:51:01 Why . diino M assams ntn ciainof activation instant almost 10-fold to causes up by AMP AMPK of Addition mechanisms sensing nutrient cellular oxygen. a in and as glucose player acts both key system for cause a AMPK can is that the and stresses AMP, sensor metabolic the in the of glucose increase of status for an two energy deprivation are the Since oxygen that compromised. or rise signal been A a 1). has (Fig. therefore cell adenylate AMP is ATP: producing the AMP left, the of in the in displacement to drop some reaction a cause kinase causes will How- that ratio ATP). stress ADP than metabolic lower any 100-fold ever, to (up low concentration AMP rvstervril ecinctlsdb dnlt kinase adenylate oxygen, by and catalysed (ATP glucose reaction catabolism of reversible by supplies the adequate maintained drives have is that A which cells AMP? in ratio, by activated ATP:ADP kinase protein high a express cells should iaino MKi epnet gnsta increase that agents to response in Ca AMPK intracellular of kinase- tivation kinase dependent ao ptemkns hshrltn h-7 ob a be LKB1 to kinase the protein Thr-172 identified the phosphorylating containing others complex kinase and to upstream We biomarkers major as activation. the used AMPK widely at now monitor phosphorylated are (Ser-79) ACC recog- site target AMPK antibodies downstream and the Thr-172, nising at 1000-fold phosphorylated recognising to AMPK up antibodies give Phospho-specific to overall. effect activation allosteric the with multiplies fAP taseicst ihntekns domain kinase the within kinases, protein site upstream is specific distinct causes phosphorylation it by a that site, catalysed the at (Thr-172), not active discovered is AMPK the author it from of the However, distinct activation. story: site allosteric whole a as to at referred AMP of ing ..cmlxsfre rmtrennietclprotein non-identical catalytic the three being from these formed subunits, complexes i.e. an h-7)adteregulatory the and Thr-172) tains iigrs ou otev eeormrccombinations heterotrimeric The twelve types. cell to between varies up expression genes, whose to multiple by rise encoded is giving subunit each subjects human lfidb h lotrcmcaim h-7 a lobe phos- also the can Ca Thr-172 to am- the mechanism. further by switch allosteric is phosphorylated the net that activation by a an plified causing triggering form, AMPK thus phorylated to dephosphorylation Thr-172, prevents AMP that of change of structural binding a causes although the protein by However, conditions, removed immediately phosphatases. normally basal is phosphorylate phosphate under of the to scope appears continuously the complex beyond Thr-172 LKB1 is The of this review. effects of this suppressor discussion tumour that although the clear that LKB1, of seems product now many gene It mediates cancer. a AMPK of i.e. development suppressor, the previously tumour inhibits been a had as LKB1 identified because discovery, exciting an euain tutr n vlto fAMP-activated of evolution and structure Regulation, MKocr nvral shtrtiei complexes, heterotrimeric as universally occurs AMPK , subjectto theCambridgeCore termsofuse,available at (8,9) + AMP > . 0-odatvto fAMPK of activation 100-fold $ AP rmlf orgt epn h AMP the keeping right, to left from 2ADP) 2 + Fg ) vni h bec fars in rise a of absence the in even 1), (Fig. rti kinase protein (2,4) 2 b + ic hsi asdb bind- by caused is this Since . hc a rge h ac- the trigger can which , atvtdkns calmodulin- kinase -activated b a and uui wihcon- (which subunit (5) g subunits Fg ) This 1). (Fig. (6,7) hswas This . b subunits (10) .In https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society hwn hti sivle nntin esn n the and sensing nutrient removal, in cannot glucose involved starvation to but is to responses glucose, response it normal high that always the containing if showing of viable medium any are a mount complex evolution. in the early kept during lacking AMPK yeast been of as Budding clues function has the interesting probable give (orthologues) the results eukaryotes, to the relatives and lower genetics, AMPK by In studied the mammals. of and function plants insects, ranging eukaryotes, cerevisae (e.g. protozoa all as of lamblia such genomes organisms unicellular the from in found readily MKi ciae ya nraei h cellular the in cell the increase of status an energy the that compromised. by signal depho- Thus, is a effects. on activated ratio, activating effect the AMP:ATP is trigger the to with for AMPK fails competition this in other ATP but bind the AMP, also allosteric sites and the Both for AMP sphorylation. required is of one that effect is explanation one but ihntenra hsooia ag le h aeof rate glucose the alter in range fluctuations physiological and normal i.e. the enzymes, glucokinase, within phosphorylating and glucose GLUT2 and transporters Hardie G. D. nucleotide, regulatory the bind that the whereas sites AMP later, two discussed regulatory contain be whose will modules function carbohydrate-binding contain 94 pcfi ernsi h yohlms xrs high express hypothalamus, the the in neurones as only ‘glucose- specific such therefore be specialised cells, not AMPK may However, sensing’ that of relevant. concentrations glucose activation physiologically low very the at cells, occurs concentrations. these glucose plasma In normal at saturated thus are eaoimi aaye yhxkns.GU1 GLUT4 high GLUT1, exhibit all hexokinase. hexokinase glucose by and subsequent catalysed in step is first metabolism the and GLUT4, or GLUT1 h MKotoou srqie o hsresponse this for and required lifespan, is their orthologue extends AMPK of considerably the the maturation also Restricting sexual but worms defined. delays the development first to early energy thought was during dietary now mammals, diet of is in which effect also longevity, occur the enhance where to systems restriction one model was organism the This of restriction. energy dietary to sponse elegans rhabditis aeo lcs aaoimadacneun nraein increase consequent reduced ratio a a culture, to and AMP:ATP in due catabolism yeast) the glucose glucose in of of (as activated rate deprived rapidly are is AMPK cells mammalian If to response the in that was view system nutrients. AMPK the carbon of the for period reinforces starvation of a this of role equivalent fasting, ancestral the is or plant starvation a for darkness Since u srqie o rwhi lent ih–akcycles light–dark light, alternate continuous in in growth for growth required for is required but not is orthologue plant the ee noigthe encoding Genes ciaino amla M-ciae protein AMP-activated mammalian of Activation https://www.cambridge.org/core (11,12) n ug eg udn yeast, budding (e.g. fungi and ) ,t utclua raim uha nematodes, as such organisms multicellular to ), h hr hudb w ie sntytclear, yet not is sites two be should there Why . hsoirlapatens Physcomitrella iaeb eaoi stresses metabolic by kinase h MKotoou sivle nre- in involved is orthologue AMPK the , . https://doi.org/10.1017/S0029665110003915 (17) (13) a otmmainclsexpress cells mammalian Most . , ntenmtd worm nematode the In . b . IPaddress: and b el ftepnra and pancreas the of cells K g m ams) h AMPK the moss), (a uuiso MKare AMPK of subunits ausfrguoe and glucose, for values 170.106.35.234 Saccharomyces , on g 29 Sep2021 at02:51:01 (14,15) subunits Giardia Caeno- (16) .In K m . t blt osiuaeftyai xdto setenext the (see oxidation expenditure acid energy fatty hence example. and stimulate for classical section) accounting to the muscle, ability skeletal is its in leptin AMPK which activates the Leptin of by multicellular released illustrated adipocytes, substances of is cytokine-like of by This adipokines, types the system. evolution other of the effects with allow the interact to to an during input occurred of adaptations that less organisms, expressed. hormonal appears ubiquitously is by still deprivation It is plasma limits AMPK glucose mammals, Nevertheless, response tight so issue. In in within and source. maintained been homoeostasis, carbon is have uni- a in glucose for to AMPK starvation of appears to role eukaryotes ancestral the cellular earlier, discussed As nrae erto fguao n deaieb the by adrenaline and to medulla and glucagon adrenal insulin responses and of of pancreas physiological secretion secretion the reduced increased as to in appears such roles AMPK hypoglycaemia, of important activation the play cells, these AMPK In the modulate activity. consequently and metabolism glucose MKi ciae,tigrn hne nCa in that changes so triggering tension activated, be oxygen is to AMPK decreasing appears lung. to catabolism the sensitive mitochondrial of to particularly types, regions order cell oxygenated in both more hypoxia, In to to flow response blood in in divert happens contract Other what lin- arteries) artery. to cells (opposite most carotid which muscle the arteries, smooth pulmonary via the ing con- it include oxygen reaching cells release the blood oxygen-sensing the to the cells response to of in 1 tent signalling breathing regulate nerves, Type to more brain afferent by hypoxia. activated onto of is neurotransmitters AMPK cells levels which 1 in Type physiological body, also the carotid are as the as such in there just cells, cells, oxygen-sensing However, during glucose-sensing specialised occurs activated. specialised as are is (such there AMPK levels to before low has ischaemia) tension pathologically oxygen to the cells drop most in hypoglycaemia, for ie sn ipiso ua uce naltrsection, downstream muscle. occur contracting later that in a effects AMPK metabolic In of the muscle. on focus human will of I biopsies using times nw oeo etni orpesaptt adhence (and Kahn appetite and repress hypothalamus, the to on is effects via leptin intake) of energy role known rcnrcin(umnr mohmuscle) cells) smooth 1 (pulmonary (Type contraction release or neurotransmitter either promote that MKi ciae nrdn kltlmsl during muscle skeletal that rodent found author in muscle exercise the activated treadmill is Winder, is conditions, Will AMPK physiological With activates oc- which normal that contraction. and under stress consumption, ATP metabolic curs accelerating A by synthesis. AMPK ATP biting ucei epnet shei,a nerpini the in interruption an ischaemia, to supply cardiac blood response in example, in for AMP:ATP occurs, muscle in This increases activation. AMPK causing and thus catabolism, limit can , subjectto theCambridgeCore termsofuse,available at h tessdsusdtu a ciaeAP yinhi- by AMPK activate far thus discussed stresses The ervto foye hpxa saohrsrs that stress another is (hypoxia) oxygen of Deprivation euaino M-ciae rti iaeby kinase protein AMP-activated of Regulation (21–23) dpknsadohrcytokines other and adipokines (27) iia owa a utbe described been just has what to Similar . n hshsbe ofimdmany confirmed been has this and , (17–20) . (28) h oewell- more The . (24–26) 2 + movement . https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society n owreshv ugse htti smdae by mediated is this that AMPK of suggested inhibition have co-workers and oditk i fet ntehypothalamus the on effects via intake food factor fguoegnssi h liver suppression the including in be effects, to gluconeogenesis its appears of this of and many tissues, for other and responsible liver the in AMPK iir ertohcfactor neurotrophic ciliary rodents in intake or food cannabinoids, increase or ghrelin all hormone hypoglycaemia, gut the with riboside, with treatment infusion 5-aminoimidazole-4-carboxamide as nucleoside such which hypothalamus, the treatments the that in agreement AMPK activate widespread also is There sivle nguoesnigi h hypothalamus AMPK the that in idea sensing the glucose support in do sup- involved but fully is model, not have this neurones ported hypothalamic in AMPK lack h lcs ntemdu trst eoedepleted become to to when meta- starts metabolism medium is oxidative (anaerobic the yeast in efficient fermentation glucose more budding the the the from in of to switch orthologue one bolism) Intriguingly, is the AMPK role. this the trigger key and of and a aerobic important, glucose roles plays of increasingly as AMPK than use becomes where such more the acids fuels endurance of blood-borne fatty exercise, for events and prolonged required running metabolism During in is m. example, 200 that anaerobic for from metabolism switch exercise, by AMPK. the aerobic of activated in independent crucial to are ratio become does and AMP:ATP AMPK the AMP phospho- in reg- bind and increases key directly (phosphorylase the because involved fructokinase) AMPK, enzymes become require again not ulatory once then do However, ATP. effects glycolysis of these glyco- generation anaerobic phosphocreatine the sprint, for a and As important as AMP. such breakdown event or gen an in ADP during change ATP, depleted little becomes is conversion of there the content that by so generated the ATP, is to ATP to phosphocreatine the In of responses of weight-lifting. much in as case, such involved pro- exercise, this be resistance during of not bouts activated may short and mainly exercise is in longed longer- changes AMPK exercise, by for expression. to caused also exercise gene responses but repeated to minutes, acute adaptations or term for AMPK seconds only within muscle. have occurring skeletal not in activation responsible studied AMPK is well of particularly consequences been metabolic The other some or AMP:ATP unclear. in AMPK, remain changes activate mechanism, agents through these which whether by mechanisms exact ies fet ndfeetcl ye,icuigIL-6 including have types, nutrients cell for different and accounting in activity, hormones effects AMPK diverse modulate cytokines, to reported of been number a nrsos ocnrcini asdb rnlcto of translocation a by caused is contraction to response in etn cigvateAioIreceptor AdipoRI the Adipo- via individuals. insulin-resistant acting or nectin, obese paradoxically is in leptin) reduced to contrast (in concentration plasma h ct nraei lcs paei kltlmuscle skeletal in uptake glucose in increase acute The h te elkonaioiei dpnci,whose adiponectin, is adipokine well-known other The eaoi fet fAPatvtdpoenkinase protein AMP-activated of effects Metabolic (39) https://www.cambridge.org/core ciaindrn ucecontraction muscle during activation n iocacid lipoic and (29) . https://doi.org/10.1017/S0029665110003915 eut ihkokotmc that mice knock-out with Results . (40) (37,38) nms fteecss the cases, these of most In . . IPaddress: (34) arpaeinhibitory macrophage , n nacmn of enhancement and 170.106.35.234 (33) (35) MKadmsl eaoim95 metabolism muscle and AMPK activates , , on Finally, . (30–32) 29 Sep2021 at02:51:01 (13) (36) (19) . . , . xrse nms te el,i hshrltdadin- and phosphorylated is AMPK isoform cells, ACC1 by other the activated like most which, in ACC expresses expressed of Muscle isoform oxidation. ACC2 acid the fatty is exercise intensity subjects. insulin-resistant in beneficial particularly MKwsivle nti effect this that in confirmed involved means, contraction various was during by AMPK activation defective AMPK rendered which was in mice, GM enkns sdfcie u h ehns ywhich by remains mechanism AMPK the via but uptake unaffected glucose defective, stimulates is pro- contraction B of insulin- phosphorylates kinase In activation family. tein insulin-dependent B same the individuals, of kinase resistant members other when protein or muscle, TBC1D1 resting insulin-activated in uptake the glucose stimulates insulin eae1i eurdfrteutk fftyaisinto the acids by muscle fatty resting of ACC2 in uptake by inhibited produced the malonyl-CoA is for and required mitochondria, the is trans- Carnitine-palmitoyl on ferase-1 the membrane. located of mitochondrial inhibitor transferase-1 outer an carnitine-palmitoyl malonyl-CoA, enzyme produces and chondria ioie MKwsatvtdadti a associated was this and uptake glucose activated skeletal increased with rat was When AMPK activating system. riboside, 5-aminoimidazole-4-carboxamide AMPK with the perfused the was on muscle mimics AMP of con- which effects and monophosphate, cells 5-aminoimidazole-4-carboxamide by nucleotide riboside up the taken to Winder 5-aminoimidazole-4- is verted nucleoside, This by the be riboside. the experiments using carboxamide might from author to this the came that vesicles and AMPK evidence storage by first mediated The intracellular membrane. from plasma GLUT4 the hc a emdae npr ypopoyaino a promoter structure of chromatin GLUT4 phosphorylation the the by modifies part at that in deacetylase mediated histone be may which 1 ohnceradmtcodilDA MKhsbeen PPAR has phosphorylate AMPK directly DNA. to mitochondrial reported and in encoded nuclear genes both mitochondrial of the expression the up-regulating promotes PPAR by co-activator biogenesis transcriptional mitochondrial regulates paeit iohnraadhneoxidation hence and mitochondria acid fatty into promotes therefore uptake contraction during AMPK by n.Ti nldsicesdepeso fGLUT4 of expression longer-term increased the includes train- of exercise This some endurance repeated ing. for by responsible induced insulin-resistant adaptations also in is AMPK beneficial is exercise another subjects. therefore why is AMPK resistance. mus- by insulin reason oxidation in with fat associated TAG of is as tissues, Stimulation other acids in fatty as of cle, storage excessive estingly, rmteriatv RbGP oteratv (Rab:GTP) active Rabs their of to called conversion (Rab:GDP) forms proteins inactive the their nucleotide-binding from promoting guanine by small enhances translocation which 1), GLUT4 (TRE2/ member TBC1D1 to family called appears domain protein BUB2/CDC16 one a of but phosphorylation membrane, GLUT4 the be plasma promotes the AMPK to which translocation by mechanisms multiple a nte aaoi aha ciae uiglow- during activated pathway catabolic Another swl steeaueefcso ucemetabolism, muscle on effects acute these as well As (51) , subjectto theCambridgeCore termsofuse,available at (44,45) u h ehns a loivledeacetylation involve also may mechanism the but , (46) hsi iia otemcaimb which by mechanism the to similar is This . hsi n esnwyrglreecs is exercise regular why reason one is This . (47) C2i soitdwt mito- with associated is ACC2 . (50) MKatvto loup- also activation AMPK . (41) usqetsuiswith studies Subsequent . g (48) co-activator-1 (42,43) niiino ACC2 of Inhibition . hr a be may There . g co-activator- (41) a which , Inter- . (49) , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society ontemo AMPK of downstream sfudt ei ihydpopoyae n active and dephosphorylated highly a in synthase be glycogen Paradoxically, state to exercise synthesis. found of after is breakdown glycogen immediately catabolic than towards however, diverted rather is glucose glucose of cell flux the increased into the contraction, during increases ytei htas otosisrate its glycogen controls in step glycogen also last is that the muscle off. catalysing synthesis skeletal ATP-requiring enzyme switched in the other be AMPK synthase, should for that target biosynthesis, sense Another as makes such therefore processes, it and develop- the diabetes. against of protection ment provide to exercise regular 6D .Hardie G. D. PPAR of 96 ytaei on ob ehshrltdimdaeyfol- immediately dephosphorylated glycogen exercise be lowing substrate to its found exercise, is although synthase during that, activated observation is paradoxical AMPK the for explanation ssi ht nafl-ie lcgnpril hthsup diameter in has a nm of that 20–30 surface only particle the is around glycogen that particle packed full-sized glycogen ends a non-reducing hypoth- 2000 in to current that, of Our is chain Chevtzoff results). (C esis unpublished a end Hardie, using non-reducing DG a maximum and lacking a units glucose reaches six inhibition the that nryi h omo T n D,btas h medium the also but ADP, and ATP of form of the availability cor- short-term in is the energy model monitors this only If not ceased. AMPK rect, exercise as rapidly soon be as would replenished it depleted, significantly became glycogen ehshrltdb rti hshtssbudt the to bound particle phosphatases be glycogen protein instead greater by would the which dephosphorylated longer to synthase, no would glycogen due open. and phosphorylate ends, inhibited more non-reducing the become become of accessibility would now structure would the AMPK and would removed branches outer be the glycogen exercise as during However, degraded glycogen. becomes of ex- phos- chains further outer thus from the it would tending preventing AMPK still module. synthase, particle glycogen may carbohydrate-binding glycogen phorylate it the full-sized via although they a particle AMPK, that In the inhibit packed to to tightly bind unable so be be would would ends non-reducing esml olcls MKi ls rxmt oits to AMPK proximity inhibits also close obtained recently glycogen in has that author part AMPK evidence the in synthase, localise may glycogen to target, module carbohydrate-binding simply the be of role the erdcdi niiul trs fdvlpn type-2 developing of risk to at Because tend individuals function faster. in diabetes mitochondrial is reduced and it be uptake production rapidly regularly, more glucose ATP up repeated both taken mitochondrial is is glucose exercise and because as easier that, becomes ensure would lcgnprilsi natclsand with cells associate intact to in complex particles the cause glycogen that modules binding hrltsgyoe ytaea ie2 euigisactiv- its reducing 2, site at ity synthase glycogen phorylates lgschrdsta ii h o-euiged of the inhibit ends particle glycogen the non-reducing activity of kinase surface the the at mimic glycogen that oligosaccharides ucecnrcincue eyrpdAPconsumption ATP rapid very causes contraction Muscle hs ogrtr dpain oedrneexercise endurance to adaptations longer-term These (54) (56) https://www.cambridge.org/core hsmyhl oesr htwe lcs uptake glucose when that ensure to help may This . The . (53) g co-activator-1 MKcnas ept xli h blt of ability the explain to help also can AMPK , b (60) (56,62) uuiso MKcnancarbohydrate- contain AMPK of subunits n eetupbihdeiec shows evidence unpublished recent and , (62) . https://doi.org/10.1017/S0029665110003915 hsmcaimwudesr ht if that, ensure would mechanism This . hsmdlpoie potential a provides model This . (52) a . ySrun1 hc sactivated is which Sirtuin-1, by . IPaddress: 170.106.35.234 (54,55) nvivo in MKphos- AMPK . (60) (57–59) , on Synthetic . 29 Sep2021 at02:51:01 While . (61) the , lobnfiilb ersigpouto fguoeby glucose is of adiponectin, production to repressing response in by gluconeogenesis occurs beneficial which also liver, activation developing the AMPK of diabetes. in type-2 risk and/or are at resistance which individuals insulin muscle, in in metabolic beneficial activation numerous particularly AMPK the by stressed caused I changes section, previous the In iaeta ssiuae yislnadb mn acids, initia- amino its regulating by protein by and translation insulin a tion protein by promotes is it stimulated and mTOR is mamma- that the (mTOR). kinase component target-of-rapamycin central stimu- its that lian as pathway has mRNA signalling translation of important lates translation An is protein. exercise into during temporarily, least insulin are who individuals hyperglycaemic. or in resistant exercise occurs of that ben- that outcomes the means uptake of eficial another glucose also glycogen, replenish rapid It to the exercise glycogen. following in of involved form is the AMPK in reserves term ypopoyaigmlil ptemregulators upstream multiple phosphorylating by lcei.AP ciaini h ie lopooe fat promotes also hyper- liver to the oxidation individuals in activation insulin-resistant AMPK of glycaemia. tendency the for nmn ri n eealsadbreie yellow a genus the berberine, of and plants vegetables present from and quercetin derived wine, fruit dye red many in quantities in resveratrol, small include in These obesity, cancer. present in even effects beverages, and beneficial AMPK diabetes have and activate type-2 to claimed also been foods medicines, have herbal and from traditional to from derived prescribed or xenobiotics now other ‘nutraceuticals’ of is number or that A worldwide. drug patients safe million a is metformin uk uce oprdt egtlfeso sprinters. or weight-lifters cause less to have not compared athletes muscles does endurance bulky why training to and help exercise hypertrophy, may muscle endurance inputs. this these why activation, and of mTOR explain synthesis all opposes protein by AMPK the induced Since for hypertrophy account muscle may hence this and acids, htti consfrisaiiyt oe lsaglucose plasma lower to ability its for accounts this that nectn agtfrnwdusamda h ramn of treatment the at aimed drugs resis- become diabetes new has insulin type-2 for AMPK with target that surprising exciting associated not an therefore strongly is is It tance. that state bolic nl,mO sas ciae uigrssac exercise resistance during activated also training is mTOR ingly, h rtcoc rgfrteteto ye2daee,acti- diabetes, type-2 now of is treatment AMPK and for vates drug remedy choice herbal first ancient the an from developed was ftasaini ucedrn contraction cessation during temporary muscle a this in for that translation evidence account of is partly There does synthesis. mechanism protein inhibits thus ftersiaoycan hsicesn ellrAMP: cellular increasing thus chain, I activates ATP respiratory complex of metformin the inhibition that mild of a shown causing by recently indirectly AMPK has author The euaino M-ciae rti iaeb drugs by kinase protein AMP-activated of Regulation , subjectto theCambridgeCore termsofuse,available at nte isnhtcptwyta ssice f,at off, switched is that pathway biosynthetic Another (63) (73) MKatvto,o h te ad niismTOR inhibits hand, other the on activation, AMPK . (68) ept hsrte rd ehns faction, of mechanism crude rather this Despite . (34) swl sb nui n yfeigamino feeding by and insulin by as well as hsrdcn A cuuain meta- a accumulation, TAG reducing thus , (71) (70) n hr sgo vdnefo rodents from evidence good is there and , (34,69) nfc,tebgaiemtomn which metformin, biguanide the fact, In . n ‘nutraceuticals’ and hc sa es atyresponsible partly least at is which , Berberis (66,67) (64,65) Interest- . sdin used > and , 100 (72) . https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society htalo hs ciaeAP u oteraiiyto ability their to due AMPK production ATP activate mitochondrial reported of these inhibition recently cause of have all We that medicine. Chinese traditional mtKie ec GAadPzr htspotthe support University the that at Dundee. Therapy Pfizer) of Transduction Signal and the of KGaA Division by Glaxo- and Merck Boehringer-Ingelheim, Trust, SmithKline, Wellcome (AstraZeneca, the Grants companies the from Programme in by 081195) Studies supported (080982; interest. were of laboratory conflicts author’s no declares author The activating by work to appear now balance, energy metformin, AMPK. of level, disorders as body treat whole to is such used the are at AMPK that balance molecules, drugs energy and signal of regulator other regula- longer- a and its also the adipokines Through and by exercise. changes by tion metabolic induced responsible acute adaptations be the to term muscle of appears skeletal and many In contraction oxygen. for cells by or specialised activated glucose in moni- is either act it by of can mammals, sensor it a In catabolism, as response of source. rate in carbon the been a toring have eukar- for may early starvation role during to its arose where that evolution, system yotic ancient an is AMPK wines fungicides. with organic treated in been higher not often have USA grapes is which in the infection, concentration where weed is fungal its to resveratrol noxious why response Also, is in a herbivores. grapes to as by poisonous produced classed is is it because and Rue Goat’s plant aeie(rmwihmtomni eie n which and activator derived AMPK product is potent natural metformin a the which itself this, by to (from infection of plant or galegine the support animals, by In by produced grazing micro-organisms. be interesting discourage may an or they and prevent that plants, is of metabolites speculation secondary all are .StrM ikU ur R Tuerk U, Riek M, Suter 4. .MnigG ht B atnzR Martinez DB, Whyte G, Manning 1. .Hri G aln i T 18)TeAMP- The (1989) ATR Sim & D Carling DG, common Hardie A 3. (1987) DG Hardie & VA Zammit D, Carling 2. .Hwe A aio ,WosA Woods M, Davison SA, Hawley 5. 5 iaecmlmn ftehmngenome. human the of complement kinase ino M-ciae rti kinase. protein AMP-activated of tion ciae rti iae–amliusrt euao flipid of regulator multisubstrate a metabolism. – kinase protein activated biosynthesis. cholesterol regulatory and the acid inactivates Lett fatty cascade of kinase enzymes protein bicyclic 1912–1934. 32207–32216. ie,adietfiaino henn-7 stemjrst at protein site AMP-activated major activates kinase. and the rat phosphorylates as from it threonine-172 kinase which of kinase identification protein and AMP-activated liver, the of ization 0 APfralsei tmlto,atvto,addeactiva- and activation, stimulation, allosteric for -AMP aeaofficinalis Galega https://www.cambridge.org/core 223 ilChem Biol J 217–222. , rnsBohmSci Biochem Trends Acknowledgements . https://doi.org/10.1017/S0029665110003915 271 Conclusions References hc loge ytenm of name the by goes also which , 27879–27887. , tal. et . IPaddress: (73) 20)Dsetn h oeof role the Dissecting (2006) 14 ,i rdcdb the by produced is ), 20–23. , tal. et tal. et 170.106.35.234 ilChem Biol J 20)Teprotein The (2002) 19)Character- (1996) Science MKadmsl eaoim97 metabolism muscle and AMPK , on (73) 29 Sep2021 at02:51:01 They . FEBS 298 281 , , 8 aSlaXve ,LcecI aaiA Varadi I, Leclerc G, Xavier Silva da 18. 1 uoN arA,Br RL Barr AJ, Barr N, Kudo 21. 0 crmo J hwM a X Fan M, Shaw RJ, McCrimmon 20. RL Batterham MA, Smith M, Claret 19. SJH Ashcroft G, Johnson IP, Salt 17. 3 usl RII iJ oe DL Coven J, Li III, RR Russell 23. 6 hlne ,Oso on 20)Snf1-related (2004) H Ronne & T Olsson M, Thelander 16. 2 asnA,Brrn ,RdrMH Rider L, Bertrand AS, Marsin 22. 5 abneP&RyR(06 niiino emieprolif- germline of Inhibition (2006) R Roy & P Narbonne 15. P Saiu R, Heath B, Xiao 12. 3 adeD,CrigD&CrsnM(98 h AMP- The (1998) M Carlson & D Carling DG, Hardie 13. kinases: protein AMP-activated/SNF1 (2007) DG Hardie 10. 4 pedJ ’onrG coahT McDonagh G, O’Connor J, Apfeld 14. KA Green SA, Hawley JW, Scott 11. .WosA ikro ,HahR Heath K, Dickerson A, Woods 9. KJ Mustard DA, Pan SA, Hawley 8. .WosA ontn R ikro K Dickerson SR, Johnstone A, Woods 7. .Hwe A oda ,Ri JL Reid J, Boudeau SA, Hawley 6. , subjectto theCambridgeCore termsofuse,available at soitdwt eraei aoy-o eesdet an are to due hearts 5 levels ischemic malonyl-CoA in in of increase decrease a reperfusion with during associated oxidation acid esn yPM n gPneurons. glucose AgRP and and regulation 2325–2336. POMC homeostasis by energy sensing for essential is expression. insulin 761–774. gene glucose-stimulated preproinsulin and in secretion kinase protein AMP-activated cell in glucose pancreatic release. low from insulin by derived activated is lines kinase protein activated et otshmccricdsucin ppoi,and apoptosis, dysfunction, pre- and cardiac uptake injury. glucose postischemic ischemic vents mediates kinase protein au nrgltn onergltr omn epne to responses hormone hypoglycemia. hypotha- counterregulatory acute ventromedial regulating the in in lamus kinase protein AMP-activated rti iae1i eddfrgot nanra day-night normal a in growth for cycle. needed light is 1 kinase protein ntesiuaino lclssdrn ischaemia. role during a glycolysis has of AMPK Biol by stimulation PFK-2 the heart in of activation and rylation K1adAP signalling. AMPK and LKB1 during eration 3004–3009. 274–284. ctlCAcarboxylase. acetyl-CoA fteekroi cell? sensors eukaryotic metabolic the subfamily: of kinase protein activated/SNF1 kinase. protein AMP-activated mammalian Nature to binding AMP energy. cellular Biol of guardians cells. conserved mammalian in kinase of Metab upstream protein acts kinase-beta AMP-activated kinase protein dulin-dependent nui-iesgast iepnin lifespan and to levels signals energy insulin-like links AAK-2 kinase protein AMP-activated adenosine mutations. of disease by binding disrupted whose is ligands modules energy-sensing form eedn rti iaekns-eai nalternative kinase. an protein is AMP-activated kinase-beta for Metab kinase kinase upstream protein dependent h ptemkns nteAPatvtdpoenkinase protein AMP-activated the in kinase cascade. upstream the ewe h K1tmrsprso,STRAD suppressor, cascade. tumor kinase LKB1 the between MO25 10 8 774–785. , a 2 2 lnInvest Clin J 1247–1255. , 449 / 21–33. , 9–19. , b urBiol Curr r ptemknssi h M-ciae protein AMP-activated the in kinases upstream are 496–500. , MOJ EMBO 0 APatvtdpoenkns niiinof inhibition kinase protein -AMP-activated .eeasdauer elegans C. ice J Biochem Biol J 13 114 Diabetes 23 2004–2008. , 2 n e Biochem Rev Ann 1900–1910. , 28. , 495–503. , ilChem Biol J 335 tal. et tal. et Development 533–539. , 57 eeomn eursPTEN, requires development tal. et b 444–450. , 20)Srcua ai for basis Structural (2007) .elegans C. tal. et tal. et 19)Hg ae ffatty of rates High (1995) tal. et tal. et tal. et el,admyregulate may and cells, tal. et 20)AMP-activated (2004) 270 tal. et tal. et tal. et tal. et 20)CSdomains CBS (2004) 20)Ca (2005) 20)Kyrl for role Key (2008) 20)Calmodulin- (2005) lnInvest Clin J tal. et 67 a e o Cell Mol Rev Nat 20)Complexes (2003) 17513–17520. , lnInvest Clin J 133 20)Phospho- (2000) 821–855. , . 20)LB is LKB1 (2003) ice J Biochem 20)Rl for Role (2003) ee Dev Genes 20)AMPK (2007) 19)AMP- (1998) 611–619. , 20)The (2004) 2 + a Current /calmo- / b 117 371 113 Cell Cell and 18 , , , , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society 1 erl M ut ,Hri DG Hardie E, Kurth GM, Merrill 41. 0 i S akJ,Nmon C Namkoong JY, Park MS, Kim 40. T Kubota W, Yano N, Kubota 35. Y Minokoshi J, Kamon T, Yamauchi 34. 2 uJ rznc T aldrsO Valladares JT, Brozinick J, Mu 42. 9 ilrE,L ,Ln L Leng J, Li EJ, Miller 39. BC Fam MJ, Watt GR, Steinberg 37. Y Ito J, Kamon T, Yamauchi 33. 6 ae L tibr R aalySL Macaulay GR, Steinberg AL, Carey 36. 3 aaooK catyA mt D Smith A, McCarthy K, Sakamoto 43. 8 atM,Dak ,Toa WG Thomas N, Dzamko MJ, Watt 38. 2 crmo J a ,Dn Y Ding X, Fan RJ, McCrimmon 32. SA Tucci E, Hubina B, Kola 31. 0 neso ,FlpsnK botCR Abbott K, Filipsson U, Andersson 30. 9 iooh ,AqirT uuaaN Furukawa T, Alquier Y, Minokoshi 29. 8D .Hardie G. D. 98 7 idrW adeD 19)Iatvto facetyl-CoA of Inactivation (1996) DG Hardie & WW Winder 27. 8 iooh ,KmY,Prn OD Peroni YB, Kim Y, Minokoshi 28. 6 yt N ero A ua P Kumar SA, Pearson CN, Wyatt 26. 5 oeto P utr J ei TH Lewis KJ, Mustard TP, Robertson 25. CN Wyatt KJ, Mustard AM, Evans 24. fet fapalpi cdmdae ysprsinof suppression by kinase. mediated 727–733. protein acid AMP-activated alpha-lipoic hypothalamic of effects yatvtn M-ciae rti kinase. protein AMP-activated 1288–1295. oxidation fatty-acid activating and by utilization glucose stimulates nectin kltlmsl fterat. in the oxidation of acid muscle fatty skeletal increases and malonyl-CoA decreases niioyfco tmltsAPatvtdpoenkns in kinase heart. protein ischaemic AMP-activated the stimulates factor inhibitory AMP-kinase mice. obese hypothalamic leptin-resistant in suppresses signaling factor neurotrophic vitro in oxidation acid kinase. protein fatty AMP-activated and via uptake glucose in and disposal humans glucose insulin-stimulated increases Interleukin-6 intake. food hypothalamus increases the in and kinase protein AMP-activated stimulates metabolic antidiabetic mediate that effects. receptors adiponectin in hypothalamus. sensing ventromedial hypoglycemia in the kinase protein AMP-activated for fLB nseea ucepeet MKactivation AMPK prevents muscle skeletal in LKB1 of muscle. skeletal hypoxia- in and 1085–1094. transport contraction- glucose in regulated kinase protein AMP-activated eessoeiyidcdislnrssac yactivating by resistance AMPK. muscle insulin skeletal obesity-induced reverses 3906–3914. ada fet i M-ciae rti kinase. protein and AMP-activated metabolic peripheral via Chem and effects central both cardiac have ghrelin and ciae rti iaepasarl ntecnrlo food of control the in role a plays intake. kinase protein activated iaergltsfo naeb epnigt omnland hormonal hypothalamus. to the responding in by signals nutrient intake food regulates kinase abxls n ciaino M-ciae rti kinase exercise. protein during AMP-activated muscle of in activation and carboxylase carotid the of function the in body? kinase protein AMP-activated tmltsftyai xdto yatvtn AMP-activated activating kinase. by protein oxidation fatty-acid stimulates ciae rti iaeadhpxcploayvasocon- pulmonary hypoxic and striction. kinase protein activated artery pulmonary 351–149. to mitochondrial hypoxia of constriction? by inhibition phosphorylation couple oxidative kinase protein activated https://www.cambridge.org/core 280 d x e Biol Med Exp Adv ilChem Biol J Nature u Pharmacol J Eur 25196–25201. , d x e Biol Med Exp Adv Nature 423 . https://doi.org/10.1017/S0029665110003915 762–769. , 279 Nature 415 12005–12008. , a Med Nat tal. et 605 . IPaddress: 339–343. , mJPhysiol J Am elMetab Cell mJPhysiol J Am 595 451 63–68. , 20)Mcohg migration Macrophage (2008) 39–43. , 578–582. , tal. et Diabetes tal. et 12 tal. et tal. et tal. et 580 tal. et Diabetes tal. et 170.106.35.234 tal. et 541–548. , tal. et Nature tal. et 4–5;discussion 147–154; , tal. et 6 tal. et tal. et 20)Cannabinoids (2005) tal. et 20)Ptnilrole Potential (2004) 55–68. , 20)Kyrlsfor roles Key (2008) tal. et tal. et tal. et 273 20)Adiponectin (2007) 20)Anti-obesity (2004) Endocrinology 270 20)Coigof Cloning (2003) 20)De AMP- Does (2006) 53 20)Arl for role A (2001) 20)Deficiency (2005) 55 E1107–E1112. , 1953–1958. , E299–E304. , 19)AICAR (1997) 428 20)Ciliary (2006) 20)Adipo- (2002) tal. et 20)Leptin (2002) 20)CNTF (2006) 2688–2697. , 20)AMP- (2004) 20)AMP- (2004) 20)AMP- (2008) a Med Nat , on a Med Nat o Cell Mol 569–574. , 29 Sep2021 at02:51:01 Biol J (2006) 147 10 6 7 , , , , 1 ae ,HnshnC tPer J St-Pierre C, Handschin S, Jager 51. KF Howlett BJ, Denderen van SL, McGee 50. 9 hn ,McenP,PhetSC Pohnert PS, MacLean D, Zheng 49. 2 at ,GratHnsZ eg JN Feige Z, Gerhart-Hines C, Canto 52. carni- mitochondrial The (1997) NF Brown & JD McGarry 48. 5 ogne B ile N ikJB Birk JN, Nielsen SB, Jorgensen 55. 6 uiN ui ,Hrha MF Hirshman N, Fujii N, Musi 46. JB Birk JT, Treebak C, Pehmoller 45. 3 oelB hla I(05 iohnra dysfunction Mitochondrial (2005) GI Shulman & BB Lowell 53. DG Hardie HA, Wilson WW, Winder 47. 4 aln adeD 18)Tesbtaeadsequence and substrate The (1989) DG Hardie & D Carling 54. 4 hnS upyJ ohR Toth J, Murphy S, Chen 44. 0 crd ,Giaae ,Nkle A Nikolaev S, Ghilagaber A, McBride 60. 2 shnahW,Szk ,BednK Breeden Y, Suzuki WG, Aschenbach 62. Opti- (1993) ED Shelton & TG Waddell E, Melendez-Hevia 61. 9 edynM odn ,Km BE Kemp I, Londono M, Bendayan 59. 8 oehn ,GpaA ihl BJ Michell A, Gupta G, Polekhina 58. 7 usnE,PnD,JmsJ James DA, Pan ER, Hudson 57. skeletal in activity synthetase Glycogen (1965) WH Danforth 56. , subjectto theCambridgeCore termsofuse,available at 860–867. ciae rti iae(MK cini kltlmuscle skeletal USA PGC-1{alpha}. in Sci of action phosphorylation direct (AMPK) via kinase protein activated 5. deacetylase histone phosphorylating transcription GLUT4 by regulates kinase protein AMP-activated protein AMP-activated by transcription kinase. GLUT-4 muscle of iepliolrnfrs ytm rmcnett molecular to concept analysis. From system. palmitoyltransferase tine n ye2diabetes. 2 type and activity. NAD( SIRT1 modulating and by bolism expenditure energy regulates Physiol kinase. AMP- Appl protein by cAMP-dependent J and carboxylase kinase acetyl-CoA protein muscle activated rat of phorylation yaino lcgnsnhs n hshrls kinase. a phosphorylase and Phospho- synthase Acta kinase. Biophys glycogen Biochim protein of AMP-activated rylation the of specificity rti iae(MK satvtdi uceo subjects of muscle exercise. in during diabetes activated 2 is type with (AMPK) kinase protein muscle. skeletal Metab contraction- 14-3-3 mouse and both in phosphorylation binding abolishes TBC1D1 signaling insulin-stimulated and AMPK of disruption n lcs paedrn contraction. during 1820. uptake glucose and euaino B11adA10b rwhfcos insulin factors, growth activators. by AMPK AS160 and and TBC1D1 of regulation iaino oeua eini h vlto fmetabolism: of molecule. evolution the glycogen in the design molecular sensor of mization a as act to kinase structure. the glycogen allows of that domain is regulatory kinase a protein AMP-activated on domain glycogen-binding glycogen microscopy. immunoelectron with by Cytochem situ Histochem subunits J in kinase revealed as protein particles AMP-activated of uceseicpoenpopaaeP1/(L(() is PP1G/R(GL)(G(M)) phosphatase protein muscle-specific Biol b oissmlrt hs eni eeiaycricarrhyth- cardiac hereditary in storage seen glycogen those causes mias. to kinase similar protein bodies AMP-activated in glyco- of control and forms synthesis. two gen of Interconversion muscle. hs iaei kltlmsl n srsosv oglucose to responsive is and muscle skeletal loading. in kinase thase Sbnttresmtblcsrs-esn oglycogen. to stress-sensing metabolic targets -Subunit 2-5 0 13 M-ciae rti iaei ie2gyoe syn- glycogen 2 site a is kinase protein AMP-activated urBiol Curr 297 867–871. , plPhysiol Appl J Diabetes 104 u Biochem J Eur E665–E675. , 12017–12022. , ilChem Biol J 82 13 219–225. , 53 861–866. , 3074–3081. , Science elMetab Cell 1012 ice J Biochem 91 57 ice J Biochem 244 1073–1083. , 963–971. , 81–86. , Nature 240 1–14. , 307 tal. et tal. et 588–593. , tal. et 384–387. , 409 9 295 mJPyilEndocrinol Physiol J Am 458 23–34. , tal. et tal. et 20)Anvldomain novel A (2003) 20)Complementary (2008) Diabetes 449–459. , tal. et 20)AMP-activated (2001) tal. et 477–483. , tal. et 1056–1060. , tal. et MOJ EMBO tal. et tal. et 20)Association (2009) tal. et tal. et 20)Regulation (2001) rcNt Acad Natl Proc 20)Genetic (2009) 20)AMPK (2003) 20)AMPK (2009) 20)AMP- (2007) 50 tal. et Diabetes 19)Phos- (1997) 20)The (2004) 20)The (2009) 20)The (2001) 921–927. , 24 + 1810– , meta- ) (2008) Curr 57 , https://www.cambridge.org/core/terms Downloaded from Proceedings of the Nutrition Society 6 ose R rze J ibl SR Kimball SJ, Crozier DR, Bolster 66. DF Egan DB, Shackelford cellular DM, mediates Gwinn TSC2 65. (2003) KL Guan & T Zhu K, Inoki 64. 7 oeA,BsaiB itsnB Vistisen B, Bisiani AJ, Rose 67. 3 e R&Bei 20)mO,tasainlcnrland control translational mTOR, (2005) J Blenis & AR Tee 63. kltlmsl hog oneuae TRsignaling. mTOR rat downregulated Chem in Biol through synthesis J protein muscle suppresses skeletal kinase protein activated survival. and growth 577–590. cell control to response energy eu nerCm Physiol type. Comp fiber Integr muscle and Regul exercise intensity on endurance dependent during is phosphorylation 4EBP1 and eEF2 seta o ciaino lcgnsnhs yexercise. by synthase glycogen Chem of Biol J activation for essential hshrlto frpo eitsamtblccheckpoint. metabolic a Cell mediates Mol raptor of phosphorylation disease. human https://www.cambridge.org/core 30 214–226. , 277 276 ei elDvBiol Dev Cell Semin 23977–23980. , 39959–39967. , . https://doi.org/10.1017/S0029665110003915 296 . IPaddress: R326–R333. , tal. et 16 20)Seea muscle Skeletal (2009) 170.106.35.234 29–37. , tal. et tal. et 20)AMPK (2008) 20)AMP- (2002) mJPhysiol J Am MKadmsl eaoim99 metabolism muscle and AMPK , on Cell 29 Sep2021 at02:51:01 115 , 1 huG yr ,L Y Li R, Myers G, Zhou 71. 2 hwR,LmaK,VsuzD Vasquez KA, Lamia RJ, Shaw 72. 3 alyS,Rs A hvzf C Chevtzoff FA, Ross SA, Hawley 73. drug a as kinase protein AMP-activated (2007) DG Hardie 70. 9 ohedP,Sl P akrKS Walker IP, Salt PA, Lochhead 69. 8 arK&EsrK(99 hshrlto fp0Sk cor- p70(S6k) of Phosphorylation (1999) K Esser & K Baar 68. , subjectto theCambridgeCore termsofuse,available at el xrsiggmasbntvrat oIetf diverse Identify activation. to AMPK variants of subunit mechanisms gamma expressing cells therapeutic and metformin. liver of in effects homeostasis glucose mediates LKB1 action. metformin of mechanism Invest in kinase protein target. nteepeso fte2kyguoegncgnsPEPCK genes gluconeogenic key 2 glucose-6-phosphatase. the insulin and of of expression effects the the on mimics riboside dazole-4-carboxamide eae ihicesdseea ucems olwn resis- following mass muscle exercise. skeletal tance increased with relates 108 nuRvPamclToxicol Pharmacol Rev Annu 1167–1174. , mJPhysiol J Am Science tal. et Diabetes 276 310 20)Rl fAMP-activated of Role (2001) C120–C127. , 1642–1646. , elMetab Cell tal. et tal. et 47 49 tal. et 185–210. , 896–903. , 20)5-aminoimi- (2000) 20)Tekinase The (2005) 21)Ueof Use (2010) 11 554–565. , Clin J